These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25290414)

  • 21. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
    Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
    Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
    Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
    Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 25. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical practice-changing trials: the HERA study paradigm.
    Zardavas D; Ades F; de Azambuja E
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1249-56. PubMed ID: 24138446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
    Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
    Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
    Gujral DM; Lloyd G; Bhattacharyya S
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):446-7. PubMed ID: 23583229
    [No Abstract]   [Full Text] [Related]  

  • 29. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
    Niculescu-Duvaz I
    Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Locoregional breast radiotherapy and concurrent treatment with trastuzumab].
    Jacob J; Kirova YM
    Bull Cancer; 2014 Jan; 101(1):40-51. PubMed ID: 24445735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies as molecular target-based therapy: trastuzumab.
    Tokuda Y
    Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.
    Ramić S; Asić K; Balja MP; Paić F; Benković V; Knežević F
    Anticancer Res; 2013 Jun; 33(6):2509-15. PubMed ID: 23749902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.
    Van den Nest M; Glechner A; Gold M; Gartlehner G
    Syst Rev; 2019 Dec; 8(1):321. PubMed ID: 31829250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous trastuzumab: drug development and current position.
    Martín Martorell P; Bermejo de Las Heras B; Pérez-Fidalgo JA; Huerta Alvaro M; Martín M; Albanell J; Lluch Hernández A
    Clin Transl Oncol; 2014 Oct; 16(10):859-64. PubMed ID: 24777594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.